VBI VACCINES INC.
Categories of dependency expected for this filer that were actually found stated in Risk Factors / MD&A.
- Filing
- 0001437749-16-026076 (10-K)
- Period
- 2015-01-01 to 2015-12-31
- XBRL tag
- us-gaap:Revenues
- Context
- d_2015-01-01_2015-12-31
- Mapping
- seed · confidence 1.00
Extracted from Risk Factors / MD&A, checked verbatim against the source text before being stored.
“VBI, through its wholly-owned subsidiaries, depends on subcontractor arrangements to facilitate the completion of its research programs.”
“Paragon will be manufacturing VBI’s clinical batches of its lead CMV vaccine candidate.”
“our ability to manufacture, or to have manufactured, any products we develop”
“VBI faces general market competition from several subsectors of the vaccine development field”
“Within the CMV vaccine space, VBI has several key competitors, some of whom are further advanced with their CMV vaccine development, as compared to VBI.”
“emerging competition and rapidly advancing technology in our industry that may outpace our technology”
“the impact of competitive or alternative products, technologies and pricing”
“eventual customer demand for the products we are currently developing”